已收盘 07-02 16:00:00 美东时间
+1.590
+4.32%
赛尔迭克斯治疗公司(纳斯达克代码:CLDX)入选分析师推荐的10只最优生物科技买入股榜单。 关键机构动作与数据: 6月10日瑞银将CLDX目标价从38美元上调至...
06-30 21:52
Celldex Therapeutics shareholders approve 3,400,000-share increase to 2021 equity plan at annual meeting Celldex held its annual shareholder meeting on June 25, 2026. Shareholders ratified PricewaterhouseCoopers as independent registered public accounting firm for the year ending Dec. 31, 2026. Inve
06-26 20:47
今日重点评级关注:HC Wainwright & Co.:维持Elicio Therapeutics"买入"评级,目标价从17美元升至23美元;Leerink Partners:维持SAB Biotherapeutics"跑赢大市"评级,目标价从7美元升至12美元
06-16 11:34
今日重点评级关注:Ascendiant Capital:维持NextTrip"买入"评级,目标价从7美元升至7.5美元;Maxim Group:维持Zevra Therapeutics"买入"评级,目标价从25美元升至35美元
06-11 09:55
UBS analyst David Dai maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $38 to $45.
06-11 01:24
Celldex will present three studies at the EAACI Congress in Istanbul, including barzolvolimab's long-term results in chronic spontaneous urticaria and cold urticaria, and CDX-622's Phase 1 data targeting mast cell pathways. Barzolvolimab, a monoclonal antibody, inhibits mast cell activity via KIT receptor targeting, showing potential as a first-in-class treatment for chronic urticarias. CDX-622, a bispecific antibody, neutralizes TSLP and SCF to ...
06-10 20:01
Gainers Co-Diagnostics (NASDAQ:CODX) shares rose 20.8% to $2.38 during Tuesday...
05-20 05:06
今日重点评级关注:瑞杰金融:上调InflaRx评级至"强烈买入",目标价从7美元升至9美元;巴克莱:维持Orchestra BioMed Hldgs"超配"评级,目标价从12美元升至13美元
05-14 14:32
今日重点评级关注:HC Wainwright & Co.:维持Artiva Biotherapeutics"买入"评级,目标价从15美元升至35美元;韦德布什:维持Cullinan Therapeutics"跑赢大市"评级,目标价从36美元升至37美元
05-11 15:43
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $45 to $48.
05-08 22:42